Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
CUTR's Cash to Debt is ranked higher than
99% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 4.48 vs. CUTR: No Debt )
CUTR' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.78
CUTR's Equity to Asset is ranked higher than
82% of the 367 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. CUTR: 0.78 )
CUTR' s 10-Year Equity to Asset Range
Min: 0.31   Max: 0.87
Current: 0.78

0.31
0.87
Interest Coverage No Debt
CUTR's Interest Coverage is ranked higher than
78% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: 117.58 vs. CUTR: No Debt )
CUTR' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: 4.73
M-Score: -3.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -7.05
CUTR's Operating margin (%) is ranked higher than
58% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. CUTR: -7.05 )
CUTR' s 10-Year Operating margin (%) Range
Min: -20.83   Max: 22.05
Current: -7.05

-20.83
22.05
Net-margin (%) -6.36
CUTR's Net-margin (%) is ranked higher than
58% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 4.71 vs. CUTR: -6.36 )
CUTR' s 10-Year Net-margin (%) Range
Min: -32.93   Max: 18.25
Current: -6.36

-32.93
18.25
ROE (%) -5.63
CUTR's ROE (%) is ranked higher than
59% of the 368 Companies
in the Global Medical Devices industry.

( Industry Median: 5.93 vs. CUTR: -5.63 )
CUTR' s 10-Year ROE (%) Range
Min: -17.53   Max: 190.78
Current: -5.63

-17.53
190.78
ROA (%) -4.37
CUTR's ROA (%) is ranked higher than
59% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 3.43 vs. CUTR: -4.37 )
CUTR' s 10-Year ROA (%) Range
Min: -14.57   Max: 18.75
Current: -4.37

-14.57
18.75
ROC (Joel Greenblatt) (%) -178.59
CUTR's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 13.35 vs. CUTR: -178.59 )
CUTR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1221.13   Max: 227.23
Current: -178.59

-1221.13
227.23
Revenue Growth (%) 9.60
CUTR's Revenue Growth (%) is ranked higher than
83% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. CUTR: 9.60 )
CUTR' s 10-Year Revenue Growth (%) Range
Min: -100   Max: 54.9
Current: 9.6

-100
54.9
EBITDA Growth (%) -29.50
CUTR's EBITDA Growth (%) is ranked higher than
56% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. CUTR: -29.50 )
CUTR' s 10-Year EBITDA Growth (%) Range
Min: -100   Max: 87.4
Current: -29.5

-100
87.4
EPS Growth (%) -24.90
CUTR's EPS Growth (%) is ranked higher than
57% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: -1.70 vs. CUTR: -24.90 )
CUTR' s 10-Year EPS Growth (%) Range
Min: -29.8   Max: 159.6
Current: -24.9

-29.8
159.6
» CUTR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

CUTR Guru Trades in Q2 2013

Chuck Royce 253,700 sh (+2271.03%)
Mario Gabelli 640,000 sh (+11.3%)
Steven Cohen Sold Out
Jim Simons 660,400 sh (-1.45%)
» More
Q3 2013

CUTR Guru Trades in Q3 2013

Charles Brandes 15,615 sh (New)
Mario Gabelli 650,000 sh (+1.56%)
Chuck Royce 253,700 sh (unchged)
Jim Simons 629,700 sh (-4.65%)
» More
Q4 2013

CUTR Guru Trades in Q4 2013

Charles Brandes 31,990 sh (+104.87%)
Mario Gabelli 680,000 sh (+4.62%)
Chuck Royce Sold Out
Jim Simons 620,200 sh (-1.51%)
» More
Q1 2014

CUTR Guru Trades in Q1 2014

Jim Simons 714,000 sh (+15.12%)
Charles Brandes 32,675 sh (+2.14%)
Mario Gabelli 650,000 sh (-4.41%)
» More
» Details

Insider Trades

Latest Guru Trades with CUTR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2013-12-31 Add 104.87%$8.39 - $10.56 $ 9.491%31990
Charles Brandes 2013-09-30 New Buy$8.89 - $10.18 $ 9.490%15615
Charles Brandes 2013-03-31 Sold Out 0.0015%$8.95 - $13.03 $ 9.49-17%0
Charles Brandes 2012-12-31 Reduce -61.65%$7.34 - $9.77 $ 9.4912%14543
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.70
CUTR's P/B is ranked higher than
85% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 3.46 vs. CUTR: 1.70 )
CUTR' s 10-Year P/B Range
Min: 0.68   Max: 5.31
Current: 1.7

0.68
5.31
P/S 1.90
CUTR's P/S is ranked higher than
78% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 3.30 vs. CUTR: 1.90 )
CUTR' s 10-Year P/S Range
Min: 0.93   Max: 7.8
Current: 1.9

0.93
7.8
PFCF 55.70
CUTR's PFCF is ranked higher than
80% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CUTR: 55.70 )
CUTR' s 10-Year PFCF Range
Min: 9.76   Max: 1164
Current: 55.7

9.76
1164
EV-to-EBIT -8.63
CUTR's EV-to-EBIT is ranked higher than
62% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 44.56 vs. CUTR: -8.63 )
CUTR' s 10-Year EV-to-EBIT Range
Min: 5.6   Max: 695.7
Current: -8.63

5.6
695.7
Current Ratio 5.59
CUTR's Current Ratio is ranked higher than
87% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. CUTR: 5.59 )
CUTR' s 10-Year Current Ratio Range
Min: 2.5   Max: 9.09
Current: 5.59

2.5
9.09
Quick Ratio 5.06
CUTR's Quick Ratio is ranked higher than
88% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 2.16 vs. CUTR: 5.06 )
CUTR' s 10-Year Quick Ratio Range
Min: 2.21   Max: 8.66
Current: 5.06

2.21
8.66

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.20
CUTR's Price/Net Cash is ranked higher than
98% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CUTR: 2.20 )
CUTR' s 10-Year Price/Net Cash Range
Min: 1.2   Max: 5.56
Current: 2.2

1.2
5.56
Price/Net Current Asset Value 1.90
CUTR's Price/Net Current Asset Value is ranked higher than
98% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CUTR: 1.90 )
CUTR' s 10-Year Price/Net Current Asset Value Range
Min: 1.07   Max: 5.01
Current: 1.9

1.07
5.01
Price/Tangible Book 1.70
CUTR's Price/Tangible Book is ranked higher than
90% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 5.99 vs. CUTR: 1.70 )
CUTR' s 10-Year Price/Tangible Book Range
Min: 0.77   Max: 20.59
Current: 1.7

0.77
20.59
Price/DCF (Projected) 2.70
CUTR's Price/DCF (Projected) is ranked higher than
85% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CUTR: 2.70 )
CUTR' s 10-Year Price/DCF (Projected) Range
Min: 0.45   Max: 3.21
Current: 2.7

0.45
3.21
Price/Median PS Value 0.90
CUTR's Price/Median PS Value is ranked higher than
84% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. CUTR: 0.90 )
CUTR' s 10-Year Price/Median PS Value Range
Min: 0.52   Max: 2.53
Current: 0.9

0.52
2.53
Earnings Yield (Greenblatt) 0.30
CUTR's Earnings Yield (Greenblatt) is ranked lower than
61% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 4.90 vs. CUTR: 0.30 )
CUTR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 17.8
Current: 0.3

0.1
17.8
Forward Rate of Return (Yacktman) -21.59
CUTR's Forward Rate of Return (Yacktman) is ranked higher than
57% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 0.97 vs. CUTR: -21.59 )
CUTR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 6.5   Max: 10
Current: -21.59

6.5
10

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Cutera, Inc., is a Delaware Corporation. It is a global medical device company which designs, develops, manufactures, markets, and services laser and light-based aesthetics systems for practitioners worldwide. The Company offer easy-to-use products based on six platforms - CoolGlide, Xeo, Solera, GenesisPlusTM, ExcelVTM, myQTM, VariLiteTM, and truSculptTM - each of which enable physicians and other qualified practitioners to perform safe and effective aesthetic procedures for their customers. CoolGlide is its first product platform, CoolGlide, was launched. This platform offers laser applications for hair removal, treatment of a range of vascular lesions, including leg and facial veins, and Laser Genesis - a skin rejuvenation procedure that reduces fine lines, reduces pore size and improves skin texture. Xeo platform can combine pulsed light and laser applications in a single system. The Xeo is a fully upgradeable platform on which a customer can use the following applications that it offers: remove unwanted hair, treat vascular lesions and rejuvenate the skin by treating discoloration, improving texture, reducing pore size and treating fine lines and laxity. Solera platform is a compact tabletop system designed to support a single technology platform. Solera systems use either infrared or pulsed light (Solera Opus) and can be used to remove unwanted hair, treat vascular lesions and rejuvenate the skin. GenesisPlus platform, which is a dedicated laser based system for performing skin rejuvenation procedures and for onychomycosis, or toenail fungus. This system has a hand piece that includes real time temperature monitoring of the treatment area, as well as a non-contact distance gauge using two aiming beams, for improving the clinical result of treatment. In addition, this system can be used to treat patients with skin concerns such as fine wrinkles, diffuse redness, rosacea, skin texture and pore size. Excel V is a vascular platform designed specifically for the core-market of Dermatologists and Plastic Surgeons. This platform provides a combination of the 532 nm green laser with Cutera's award winning 1064 nm Nd:YAG technology, to provide a single, compact and efficient system that treats the entire range of cosmetic vascular conditions, without the need for costly consumables. myQ is an Italian Original Equipment Manufacturer (OEM) of laser technologies ─ to market and sell the myQ series of Q-switched lasers in Japan. VariLite is a dual wavelength ─ 532 nm and 940 nm ─ laser system for vascular, benign pigmented and cutaneous lesions. This system supports treatment of all Fitzpatrick skin types from I to VI and is an economical system with no disposables. truSculpt platform is a 25cm2 hand piece. truSculpt is a high-powered radio frequency ("RF") platform designed for the non-invasive body contouring market. This system is designed to treat all body areas and with its unique electrode design is able to achieve comfortab
» More Articles for CUTR

Headlines

Articles On GuruFocus.com
Chuck Royce's Top Five Second Quarter Portfolio Increases Aug 07 2013 
Gurus Buy Micro Caps – Bamboo Toilet Paper Jul 24 2013 
Guru Weekly Real Time Update Jul 05 2013 
Mario Gabelli and Jean-Marie Eveillard's Real Time Increases Jul 02 2013 
Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 
Comment for Benjamin Graham Net Current Asset Value Screener Jun 03 2011 

More From Other Websites
CUTERA INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 31 2014
Cutera Appoints Miguel Pardos as Executive Vice President of International Jul 22 2014
Cutera Appoints Miguel Pardos as Executive Vice President of International Jul 22 2014
Cutera, Inc. to Announce Results for the Second Quarter Ended June 30, 2014 Jul 15 2014
Cutera, Inc. to Announce Results for the Second Quarter Ended June 30, 2014 Jul 15 2014
Cutera (CUTR) is in Overbought Territory: What's Next? Jul 02 2014
Cutera, Inc. (CUTR) in Focus: Stock Adds 7.1% in Session Jun 30 2014
CUTERA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 19 2014
CUTERA INC Financials May 16 2014
Cutera's (CUTR) CEO Kevin Connors on Q1 2014 Results - Earnings Call Transcript May 10 2014
Cutera, Inc. Earnings Call scheduled for 5:00 pm ET today May 08 2014
Cutera reports Q1 EPS (26c), consensus (16c) May 08 2014
CUTERA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 08 2014
CUTERA INC Files SEC form 10-Q, Quarterly Report May 08 2014
Cutera Reports First Quarter 2014 Results May 08 2014
Q1 2014 Cutera, Inc. Earnings Release - After Market Close May 08 2014
Nasdaq stocks posting largest percentage decreases Apr 14 2014
CUTERA INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements... Apr 04 2014
Cutera Introduces Two New Laser Systems Mar 20 2014
CUTERA INC Files SEC form 10-K, Annual Report Mar 18 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide